In the fall of 2012, just before Al Gilman's departure, MD Anderson officials cracked down on internal critics.
The Cancer Letter invited Jedd Wolchok, associate attending physician and chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, to describe the workings of the just-announced Parker Institute for Cancer Immunotherapy.
A foundation established by Silicon Valley entrepreneur Sean Parker—founder of Napster and first president of Facebook—has committed $250 million to research in cancer immunotherapy.
Michael Caligiuri was named president-elect by the members of the American Association for Cancer Research. He will officially become president-elect at the AACR's annual meeting in New Orleans, April 16-20, and will assume the presidency at the 2017 annual meeting.
The Oncology Research Information Exchange Network and M2Gen formed a bioinformatics collaboration with Celgene Corp.
FDA granted permission to an Irish company to market the “PneumoLiner,” a first-of-its-kind containment system indicated for isolating and containing uterine tissue during a minimally invasive hysterectomy or myomectomy. The agency announced its action April 7.
NCI announced a panel of advisors to inform the scientific direction and goals of Vice President Joe Biden's National Cancer Moonshot Initiative.
Over 70 deans and directors of public health programs and institutes signed a letter March 21 asking the White House for to prioritize federal investments in public health and cancer prevention.
December 2008, May 2009End-of-phase II meetings between AVEO Pharmaceuticals Inc. and FDA result in agreement concerning the design of the phase III trial of tivozanib for advanced renal cell carcinoma.
The Securities and Exchange Commission March 29 announced fraud charges against AVEO Pharmaceuticals Inc., a biotechnology company, and three of its former executives.
